Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.05
Bid: 2.01
Ask: 2.04
Change: -0.05 (-2.41%)
Spread: 0.03 (1.493%)
Open: 2.05
High: 2.09
Low: 2.00
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

Mon, 20th Dec 2021 11:41

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 27% at 7.72 pence, 12-month range 4.80p-13.85p. The drug discovery and development company completes GBP3.6 million fundraise via placing and subscription of 32.3 million shares at 11.00 pence each. This is an 80% premium to Friday's closing price of 6.10p. Additionally, ImmuPharma secures a GBP2.2 million subscription from investment firm Lanstead.

----------

Proteome Sciences PLC, up 6.1% to 5.20p, 12-month range 3.07p-10.00p. The drug development services provider wins a new contract in excess of GBP1 million from an unnamed "major pharmaceutical company". Under the terms of the contract, Proteome will analyse large cohorts of clinical samples from a phase 3 clinical trial. Work is expected to start early in the first quarter of 2022

----------

AIM - LOSERS

----------

ThinkSmart Ltd, down 21% at 64.22p, 12-month range 51.00p-115.00p. The Australian digital payments platform reaches an agreement with Afterpay to sell its remaining 10% stake in Clearpay in exchange for 1.7 million shares in Afterpay, worth GBP73.4 million. The disposal will be put to a vote of ThinkSmart shareholders at a meeting on January 14, it adds.

----------

Hurricane Energy PLC, down 14% at 3.60p, 12-month range 0.59p-5.30p. The oil and gas company completes a review into events that led to the rejection of its restructuring plan by the High Court of Justice of England & Wales. The review, overseen by Hurricane's non-executive directors and carried out by an independent solicitor, found that the company's prior board "discharged their fiduciary duties diligently and in good faith". The non-executive directors have agreed following the review that no further action is necessary, and that time and resources should now go towards maximising the future revenue and potential of the company.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
4 Nov 2015 10:44

ImmuPharma's Lupuzor trial on track for 2017 completion

(ShareCast News) - ImmuPharma has reached a number of important milestones in the phase three clinical trial of Lupuzor. The AIM listed company provided an update to the market on Wednesday about the drug trial, its lead programme for the potential breakthrough compound for life threatening auto imm

Read more
4 Nov 2015 10:31

WINNERS & LOSERS SUMMARY: Housebuilders And Estate Agents Torn Down

Read more
4 Nov 2015 08:56

ImmuPharma Says Lupuzor Trials Set To Start In US This Year

Read more
30 Sep 2015 09:29

ImmuPharma Appoints Non-Executive Chairman As Loss Narrows

Read more
29 Jul 2015 09:16

ImmuPharma Says Chairman And Co-Founder Richard Warr Dies

Read more
27 Jul 2015 07:08

ImmuPharma Secures Financing To Continue Lupuzor Progress (ALLISS)

Read more
29 May 2015 07:28

LONDON MORNING BRIEFING: AB Foods Lifted To Buy From Sell By Goldman

Read more
29 May 2015 05:17

AGM, EGM Calendar - Week Ahead

Read more
28 May 2015 16:28

AGM, EGM Calendar - Week Ahead

Read more
6 May 2015 08:11

ImmuPharma Chairman Takes Leave To Deal With Health Issue

Read more
30 Apr 2015 09:37

Immupharma To Focus On Lupuzor, 2014 Loss Narrows On Trial End

Read more
11 Feb 2015 12:18

Immupharma Says Cancer Therapy Trial Meets Primary Objective

Read more
22 Jan 2015 12:00

UK MIDDAY BRIEFING: Royal Mail Up As It Meets Low Expectations

Read more
22 Jan 2015 11:19

UK WINNERS & LOSERS: Oxford Instruments Falls On Another Warning

Read more
22 Jan 2015 08:32

ImmuPharma Shares Up 22% On Simbec-Orion Lupuzor Agreement

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.